Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody

Patent metadata

Field	Value
Publication number	US-2024182557-A1
Application number	US-202318383310-A
Country	US
Kind code	A1
Filing date	Oct 24, 2023
Priority date	Sep 24, 2018
Publication date	Jun 6, 2024
Grant date	—

Abstract

Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

First claim

What is claimed:

1 . A method of treating moderately to severely active ulcerative colitis (UC) in a subject in need thereof, comprising:
(a) at week 0 of the treatment, intravenously administering to the subject an anti-IL-12/IL-23p40 antibody at a dosage of (1) 260 mg if the subject weighs ≤55 kg, (2) 390 mg if the subject weighs >55 kg and ≤85 kg, or (3) 520 mg if the subject weighs >85 kg; and (b) at week 8 of the treatment and further in a maintenance regimen of every 8 weeks or 12 weeks thereafter, subcutaneously administering to the subject the antibody at a dosage of 90 mg, wherein the antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: a complementarity determining region heavy chain 1 (CDRH1) amino acid sequence of SEQ ID NO:1, a CDRH2 amino acid sequence of SEQ ID NO:2, and a CDRH3 amino acid sequence of SEQ ID NO:3; and the light chain variable region comprising: a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:4, a CDRL2 amino acid sequence of SEQ ID NO:5, and a CDRL3 amino acid sequence of SEQ ID NO:6, and wherein after treatment, the subject is a responder by at least one measure of response selected from the group consisting of: (i) having a clinical remission based on at least one of the global definition of clinical remission with Mayo score ≤2 points with no individual subscore >1 and the US definition of clinical remission with absolute stool number ≤3, rectal bleeding subscore of 0 and Mayo endoscopy subscore of 0 or 1, (ii) having an endoscopic healing with a Mayo endoscopy subscore of 0 or 1, (iii) achieving a clinical response based on the Mayo endoscopy subscore, (iv) having improvements from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) score, (v) having a mucosal healing, (vi) having a decrease from baseline in Mayo score, and (vii) in clinical response as determined by a decrease from baseline in the Mayo score by ≥30% and ≥3 points and a decrease from baseline in the rectal bleeding subscore ≥1 points or a rectal bleeding subscore of 0 or 1.

2 . The method of claim 1 , wherein after treatment, the subject is a responder by at least one measure of response selected from the group consisting of: (i) having an endoscopic healing with a Mayo endoscopy subscore of 0 or 1, (ii) achieving a clinical response based on the Mayo endoscopy subscore, (iii) having improvements from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) score, (iv) having a mucosal healing, (v) having a decrease from baseline in Mayo score, and (vi) in clinical response as determined by a decrease from baseline in the Mayo score by ≥30% and ≥3 points and a decrease from baseline in the rectal bleeding subscore ≥1 points or a rectal bleeding subscore of 0 or 1.

3 . The method of claim 1 , wherein after treatment, the subject is in corticosteroid-free clinical remission at least 44 weeks after week 0.

4 . The method of claim 1 , wherein the subject achieves a clinical remission based on at least one of the global definition and the US definition by week 16 of the treatment, and further the clinical remission continues at least 44 weeks after week 0.

5 . The method of claim 1 , wherein the subject had previously failed or was intolerant of at least one therapy selected from the group consisting of an anti-TNF, vedolizumab, corticosteroids, azathioprine (AZA), and 6 mercaptopurine (6 MP), or the subject had demonstrated corticosteroid dependence.

6 . The method of claim 5 , wherein the subject had previously demonstrated corticosteroid dependence, and after treatment the subject is in corticosteroid-free clinical remission at least 44 weeks after week 0.

7 . The method of claim 1 , wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO:7 and a light chain variable region of the amino acid sequence of SEQ ID NO:8.

8 . The method of claim 1 , wherein the antibody comprises a heavy chain of the amino acid sequence of SEQ ID NO:10 and a light chain of the amino acid sequence of SEQ ID NO:11.

9 . The method of claim 1 , wherein:
in (a), the antibody is in a first pharmaceutical composition comprising 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt, dehydrate, at pH 6.0; or in (b) the antibody is in a second pharmaceutical composition comprising 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0.

10 . The method of claim 1 , wherein:
in (a), the antibody is in a first pharmaceutical composition comprising 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt, dehydrate, at pH 6.0; and in (b) the antibody is in a second pharmaceutical composition comprising 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0.

11 . A method of treating moderately to severely active ulcerative colitis (UC) in a subject in need thereof, comprising:
(a) at week 0 of the treatment, intravenously administering to the subject an anti-IL-12/IL-23p40 antibody at a dosage of (1) 260 mg if the subject weighs ≤55 kg, (2) 390 mg if the subject weighs >55 kg and ≤85 kg, or (3) 520 mg if the subject weighs >85 kg; and (b) at week 8 of the treatment and further in a maintenance regimen of every 8 weeks or 12 weeks thereafter, subcutaneously administering to the subject the antibody at a dosage of 90 mg, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO:7 and a light chain variable region of the amino acid sequence of SEQ ID NO:8, and wherein after treatment, the subject is in corticosteroid-free clinical remission at least 44 weeks after week 0.

12 . The method of claim 11 , wherein the subject archives a clinical remission based on at least one of the global definition and the US definition by week 16 of the treatment, and further the clinical remission continues at least 44 weeks after week 0.

13 . The method of claim 11 , wherein the subject had previously failed or was intolerant of at least one therapy selected from the group consisting of an anti-TNF, vedolizumab, corticosteroids, azathioprine (AZA), and 6 mercaptopurine (6 MP), or the subject had demonstrated corticosteroid dependence.

14 . The method of claim 13 , wherein the subject had demonstrated corticosteroid dependence, and after treatment the subject is in corticosteroid-free clinical remission at least 44 weeks after week 0.

15 . The method of claim 11 , wherein the antibody comprises a heavy chain of the amino acid sequence of SEQ ID NO:10 and a light chain of the amino acid sequence of SEQ ID NO:11.

16 . The method of claim 11 , wherein:
in (a), the antibody is in a first pharmaceutical composition comprising 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt, dehydrate, at pH 6.0; or in (b) the antibody is in a second pharmaceutical composition comprising 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbate 80, at pH 6.0.

17 . The method of claim 11 , wherein:
in (a), the antibody is in a first pharmaceutical composition comprising 10 mM L-histidine, 8.5% (w/v) sucrose, 0.04% (w/v) polysorbate 80, 0.4 mg/mL L-methionine, and 20 μg/mL EDTA disodium salt, dehydrate, at pH 6.0; and in (b) the antibody is in a second pharmaceutical composition comprising 6.7 mM L-histidine, 7.6% (w/v) sucrose, 0.004% (w/v) polysorbat

Assignees

• Janssen Biotech Inc

Inventors

• Johanns Jewel
• Li Katherine
• Marano Colleen
• Strauss Richard
• Zhang Hongyan
• O'Brien Christopher
• Adedokun Omoniyi
• Shields-Tuttle Kimberly

Classifications

• C07K2317/515

  Complete light chain, i.e. VL + CL · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• A61K2039/54

  characterised by the route of administration · CPC title